- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10)
35 result(s) found for: Codon.
Displaying page 1 of 2.
EudraCT Number: 2018-000618-39 | Sponsor Protocol Number: Sym004-13 | Start Date*: 2018-10-23 |
Sponsor Name:Symphogen A/S | ||
Full Title: A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Met... | ||
Medical condition: Metastatic Colorectal Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004819-31 | Sponsor Protocol Number: IN-CRC-001 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:IN3BIO | |||||||||||||
Full Title: A Phase I/II, multi-centre, open-label, adaptive design, umbrella study assessing the safety, tolerability, immunogenicity and efficacy of IN01 in combination with small-molecule inhibitors in two ... | |||||||||||||
Medical condition: colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022951-49 | Sponsor Protocol Number: 20100007 | Start Date*: 2011-06-06 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefracto... | |||||||||||||
Medical condition: Chemorefractory, Wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS), Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) EE (Completed) LV (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005428-41 | Sponsor Protocol Number: 02044190615-01 | Start Date*: 2014-12-01 | ||||||||||||||||
Sponsor Name:Department of experimental and clincial medicine "F. Magrassi" | ||||||||||||||||||
Full Title: Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer | ||||||||||||||||||
Medical condition: The present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirim... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000739-28 | Sponsor Protocol Number: CT-AMT-060-04_(CSL220_1002) | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered t... | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017384-42 | Sponsor Protocol Number: 838 | Start Date*: 2010-05-17 | |||||||||||
Sponsor Name:Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
Full Title: Safety and efficacy of the addition of simvastatin to cetuximab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage ... | |||||||||||||
Medical condition: k-ras mutant advanced or metastatic colorectal cancer failing prior 5-FU, oxaliplatin, and irinotecan containing regimens. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000463-40 | Sponsor Protocol Number: OCTO_049 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Sequential Phase I study of MEK1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type(with aberrant c-MET) Colorectal Cancer | |||||||||||||
Medical condition: Cancer. Solid tumours in the escalation phase and colorectal cancer in the expansion groups. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002343-14 | Sponsor Protocol Number: RAG1-2019-01 | Start Date*: 2020-09-25 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY FOR RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY | ||
Medical condition: Patients with severe combined immunodeficiency (SCID) based on a genetic defect in the Recombinase Activating Gene 1 (RAG1) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002460-33 | Sponsor Protocol Number: 005-IRCC-10IIS-14 | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS | |||||||||||||
Full Title: ANTI MEK THERAPY WITH REFAMETINIB TO PREVENT RESISTANCE TO EGFR-TARGETED TREATMENT IN METASTATIC COLORECTAL CANCERS | |||||||||||||
Medical condition: metastatic colorectal carcinoma (mCRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007834-21 | Sponsor Protocol Number: | Start Date*: 2008-04-07 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: FLOX + Erbitux. 1. line treatment to patients with metastatic colorectal cancer and wild type K-RAS tumor. A phase II study. | |||||||||||||
Medical condition: Patients with metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002333-29 | Sponsor Protocol Number: GEMCAD-1601 | Start Date*: 2017-04-19 | |||||||||||
Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo) | |||||||||||||
Full Title: Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third wit... | |||||||||||||
Medical condition: Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005579-42 | Sponsor Protocol Number: CT-AMT-060-01 | Start Date*: 2015-03-20 | |||||||||||
Sponsor Name:uniQure biopharma B.V. | |||||||||||||
Full Title: A phase I/II, open-label, uncontrolled, single-dose, dose-ascending, multi-centre trial investigating an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) ... | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000410-18 | Sponsor Protocol Number: 061002 | Start Date*: 2011-05-05 |
Sponsor Name:Baxter Innovations GmbH | ||
Full Title: A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS... | ||
Medical condition: Prevention of inhibitor formation, and immune tolerance induction in patients with severe and moderately severe hemophilia A by early and low-dose prophylactic ADVATE therapy | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male | |
Trial protocol: AT (Prematurely Ended) DE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) BG (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001928-19 | Sponsor Protocol Number: C12-2 | Start Date*: 2014-01-23 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study. | |||||||||||||
Medical condition: Unresectable Wild-Type KRAS Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001203-36 | Sponsor Protocol Number: CI-IPOP.22-2012 | Start Date*: 2014-02-07 | ||||||||||||||||
Sponsor Name:Instituto Português de Oncologia do Porto Francisco Gentil, EPE | ||||||||||||||||||
Full Title: Phase II trial of the addition of Lapatinib to Capecitabine versus Capecitabine alone as radio-sensitizers in KRAS wild type resectable rectal cancer | ||||||||||||||||||
Medical condition: Rectal cancer stage II Rectal cancer stage III | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002080-21 | Sponsor Protocol Number: DETECT-01 | Start Date*: 2011-07-21 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Open-label phase 2 study of dacarbazine in patients with metastatic colorectal carcinoma based on expression of O6-methylguanine-DNA-methyltransferase (MGMT) | |||||||||||||
Medical condition: Metastatic colorectal carcinoma (mCRC) refractory to fluoropyrimidine-, irinotecan-, oxaliplatin- (if KRAS mutated) and panitumumab- or cetuximab- (if KRAS wild type) containing regimens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001656-19 | Sponsor Protocol Number: RP-L301-0119 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon O... | |||||||||||||
Medical condition: Pyruvate kinase deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014452-30 | Sponsor Protocol Number: 30012009 | Start Date*: 2010-03-29 | |||||||||||
Sponsor Name:Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
Full Title: Safety and efficacy of the addition of simvastatin to panitumumab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stag... | |||||||||||||
Medical condition: k-ras mutant advanced or metastatic colorectal cancer failing prior 5FU, oxaliplatin and irinotecan containing regimens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004884-19 | Sponsor Protocol Number: LENTICOL-F | Start Date*: 2016-05-24 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB) | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001490-33 | Sponsor Protocol Number: UC-0110/1608 | Start Date*: 2016-10-25 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis. | |||||||||||||
Medical condition: RAS and B-RAF wild-type metastatic colorectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
